Conbercept is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in Phase III for Branch Retinal Vein Occlusion. According to GlobalData, Phase III drugs for Branch Retinal Vein Occlusion have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Conbercept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Conbercept overview
Conbercept (Langmu) is a recombinant fusion protein composed of the second Ig domain of VEGFR1 and the third and fourth Ig domains of VEGFR2 to the constant region (Fc) of human IgG1. It is formulated as ophthalmic Injection meant for an Intravitreal route of administration. Conbercept is indicated for the treatment of wet age-related macular degeneration (AMD).
It is under development for the treatment of retinoblastoma, diabetic macular edema, neovascular age-related macular degeneration and macular edema caused by central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
Chengdu Kanghong Pharmaceuticals Group overview
Chengdu Kanghong Pharmaceuticals Group (Kanghong Pharmaceuticals) develops, manufactures and markets Chinese medicines, chemical drugs and biological products. It offers products for the treatment of medical conditions related to the central nervous system, ophthalmology, digestive system, gastrointestinal and diabetes among others. Kanghong Pharmaceutical products include Lumitin, Bosiqing, Bolexin, Danshu, Xinluona, Shuganjieyu, Yiqing, Keluoxin, Yitanning and Xuanmaiganju. The company offers its products in the form of dispersible tablets, ophthalmic injections, oral drugs, detoxification drugs and antiviral medicines. Kanghong Pharmaceuticals is headquartered in Chengdu, Sichuan, China.
For a complete picture of Conbercept’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
